Does Moderate Potassium Supplementation Lower Blood Pressure in Essential Hypertension? a Double Blind Randomised Crossover Trial Using Slow Potassium and Placebo

1982 ◽  
Vol 63 (3) ◽  
pp. 45P-45P
Author(s):  
S.J. Smith ◽  
N.D. Markandu ◽  
R.A. Banks ◽  
G.A. Sagnella ◽  
G.A. Macgregor
Keyword(s):  
Blood Pressure ◽  
Essential Hypertension ◽  
Crossover Trial ◽  
Lower Blood Pressure ◽  
Double Blind ◽  
Potassium Supplementation ◽  
Lower Blood ◽  
Slow Potassium

scholarly journals Nitrate-rich vegetables do not lower blood pressure in individuals with mildly elevated blood pressure: a 4-wk randomized controlled crossover trial

2018 ◽  
Vol 107 (6) ◽  
pp. 894-908 ◽  
Author(s):  
Lauren C Blekkenhorst ◽  
Joshua R Lewis ◽  
Richard L Prince ◽  
Amanda Devine ◽  
Nicola P Bondonno ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Crossover Trial ◽  
Elevated Blood Pressure ◽  
Elevated Blood ◽  
Lower Blood Pressure ◽  
Randomized Controlled ◽  
Lower Blood

Essential hypertension—definition, epidemiology, and pathophysiology

2010 ◽  
pp. 3023-3039
Author(s):  
Bryan Williams
Keyword(s):  
Blood Pressure ◽  
Essential Hypertension ◽  
Cardiovascular Risk ◽  
High Blood Pressure ◽  
Clinical Benefit ◽  
Lower Blood Pressure ◽  
Significant Clinical Benefit ◽  
Lower Blood ◽  
Absolute Cardiovascular Risk

‘Essential hypertension’ is high blood pressure for which there is no clearly defined aetiology. From a practical perspective, it is best defined as that level of blood pressure at which treatment to lower blood pressure results in significant clinical benefit—a level which will vary from patient to patient depending on their absolute cardiovascular risk....

Plasma Noradrenaline Concentration and Blood Pressure in Essential Hypertension, Phaeochromocytoma and Depression

1974 ◽  
Vol 48 (s2) ◽  
pp. 239s-242s ◽  
Author(s):  
W. J. Louis ◽  
A. E. Doyle ◽  
S. N. Anavekar
Keyword(s):  
Blood Pressure ◽  
Essential Hypertension ◽  
Endogenous Depression ◽  
Plasma Noradrenaline ◽  
Lower Blood Pressure ◽  
Normal Range ◽  
Plasma Noradrenaline Concentration ◽  
Noradrenaline Concentration ◽  
Lower Blood ◽  
Blood Pressures

1. Mean plasma noradrenaline concentration was elevated in forty-four patients with established essential hypertension. Eighteen of these hypertensive patients had resting plasma noradrenaline concentrations in the normal range. 2. Patients with endogenous depression had higher mean plasma noradrenaline concentrations but significantly lower blood pressure than patients with essential hypertension. 3. Patients with phaeochromocytoma had plasma noradrenaline concentrations twenty-eight times greater than those found in essential hypertension, but blood pressures were less than 20% higher. 4. It is concluded that excess of sympathetic drive only partly explains the level of the blood pressure in essential hypertension.

scholarly journals Effects of sang-qi granules on blood pressure and endothelial dysfunction in stage I or II hypertension: study protocol for a randomized double-blind double-simulation controlled trial

Trials ◽  
2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Haoyue Shi ◽  
Deshuang Yang ◽  
Jiajun Qiao ◽  
Rui Sun ◽  
Ruihan Li ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Endothelial Dysfunction ◽  
Controlled Trial ◽  
Stage I ◽  
Vascular Endothelial ◽  
Lower Blood Pressure ◽  
Double Blind ◽  
Endothelial Cell Function ◽  
Self Rating ◽  
Lower Blood

Abstract Background Worldwide, hypertension is an important public health challenge because of its high prevalence and the concomitant risks of cardiovascular disease. It induces half of the coronary heart disease and approximately two-thirds of the cerebrovascular disease burden. Vascular endothelial dysfunction has important roles in the pathophysiology of essential hypertension. Types I and II hypertension can be treated with sang-qi granules (SQG), a Chinese herbal formula. Several experimental studies on animals have shown that SQG can lower blood pressure and myocardial fibrosis by suppressing inflammatory responses. However, no standard clinical trial has confirmed this. Whether SQG can improve endothelial cell function is unknown. Methods/design In this randomized double-blind double-simulation controlled trial, 300 patients with stage I or II hypertension will be recruited and randomly allocated in a 1:1:1 ratio to group A (treatment with SQG and placebo instead of Losartan), group B (treatment with Losartan and placebo instead of SQG), and group C (treatment with SQG and Losartan). In this study, 10 g of SQG (or its placebo) will be administrated twice a day and 50 mg of Losartan (or its placebo) will be administrated once in the morning. The primary endpoint is the drug efficiency for each of the three groups. The secondary endpoints are the change in average systolic and diastolic blood pressure during the day and the night, the change in the rate at which blood pressure drops at night, assessment of target organ damage (heart rate variability, ankle–brachial pressure index, and pulse wave velocity), assessment of any improvement in symptoms (Hypertension Symptom Scale, syndrome integral scale in traditional Chinese medicine, Pittsburgh Sleep Quality Index Scale, Self-Rating Anxiety Scale, Self-Rating Depression Scale, and the 36-Item Short Form Health Survey), blood lipids, serum indicators of vascular function (changes in serum levels of ET-1, TXA2, NO, and PGI2), and safety indicators. Discussion This study aims to provide clinical evidence on the efficacy and safety of SQG in the treatment of hypertension. Moreover, the possible mechanism by which SQG may lower blood pressure will be explored by observing the protective effect of SQG on vascular endothelial function, as well as its effect on related clinical symptoms, risk factors, and the target organs of hypertension. Trial registration Chinese Clinical Trials Registry, ChiCTR1800016427. Registered on 1 June 2018.

Does Increasing Potassium Intake Lower Blood Pressure in Essential Hypertension?

1984 ◽  
Vol 6 ◽  
pp. S244 ◽  
Author(s):  
Graham A. MacGregor ◽  
Stephen J. Smith ◽  
Nirmala D. Markandu ◽  
Giuseppe A. Sagnella
Keyword(s):  
Blood Pressure ◽  
Essential Hypertension ◽  
Lower Blood Pressure ◽  
Potassium Intake ◽  
Lower Blood

scholarly journals How does potassium supplementation lower blood pressure?

2012 ◽  
Vol 302 (9) ◽  
pp. F1224-F1225 ◽  
Author(s):  
Alicia A. McDonough ◽  
Mien T. X. Nguyen
Keyword(s):  
Blood Pressure ◽  
Lower Blood Pressure ◽  
Potassium Supplementation ◽  
Lower Blood
Sign in / Sign up

Export Citation Format

Share Document